@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix go: . @prefix ncr: . @prefix ProteinComplex: . @prefix hasAgent: . @prefix RNA: . @prefix rgd: . @prefix geneProductOf: . @prefix species: . @prefix occursIn: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { ncr:AP-1%20Complex a ProteinComplex: . sub:_1 hasAgent: ncr:AP-1%20Complex; a go:0042789 . sub:_2 geneProductOf: rgd:2307; a RNA: . sub:_3 occursIn: species:10116; rdf:object sub:_2; rdf:predicate belv:increases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "tscript(complex(NCR:\"AP-1 Complex\")) -> r(RGD:Cd44)" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "1.4" . sub:_4 prov:value "To determine the functional importance of this AP-1 site, we used site-directed mutagenesis to generate a 1.4 kb CD44 5'-promoter construct containing an AP-1 site mutation, CD44(-1,262/+109AP-1m). A comparable mutation of the AP-1 motif in the human CD44 promoter (TTAGTCA to CTAGGCA) disrupts the function of this site (53) . In comparison with the native CD44(-1,262/+109) construct, the CD44(-1,262/+109AP-1m) construct displayed a 51% reduction in promoter activity in RASMC after stimulation by IL-1ß "; prov:wasQuotedFrom pubmed:10657993 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:10657993; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:29:49.908+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }